期刊文献+

卡维地洛对慢性重症心衰患者心室重塑及心功能的影响 被引量:4

原文传递
导出
摘要 目的探讨卡维地洛对慢性重症充血性心力衰竭(CHF)患者心室重塑及心脏功能的影响。方法选择重症CHF患者43例,均接受常规CHF治疗(洋地黄、利尿剂、血管紧张素转换酶抑制剂),并随机分为治疗组和对照组。治疗组在常规CHF治疗的基础上加用卡维地洛。观察两组患者治疗前、治疗后6个月的左室舒张末内径(LVEDd)、左室收缩末内径(LVESd)、左室射血分数(LVEF)、左室重量指数(LVMI)及心率、血压的变化。结果治疗6个月后,与对照组比较,治疗组心率减慢,LVEDd、LVESd、LVEF和LVMI改善的程度更明显,差异有统计学意义。结论卡维地洛可显著逆转心室重塑,明显改善CHF患者心脏功能,疗效安全可靠。
出处 《临床医学》 CAS 2008年第2期57-58,共2页 Clinical Medicine
  • 相关文献

参考文献4

二级参考文献10

  • 1Wallukat G, Fu ML, Maggnusson Y, et al. Agonistic effects of anti-peptide autibodies and autoantibodies directed against adrenergic and cholinergic rcceptor:absence of desensitization. Blood Pressure, 1996,5(Suppl 3):31-36.
  • 2Podlowski S, Luther HP, Morwinski R, et al. Agonistic anti-β1- adrenergic rcceptor autoantibodies from cardiomyopathy patients reduce the β1- adrenergic rcceptor expression in neonatal rat cardiomyocytes. Circulation,1998,98:2470-2476.
  • 3Luther HP, Homuth V, Wallukat G, et al. α1-adrenergic receptor antibodies in patients with primary hypertension. Hypertension,1997,29:678-682.
  • 4Nakajima T, Ma J, Zida H, et al. Inhibitory effects of carvedilol on calcium channels in vascular smooth muscle cell. Jpn Heart J, 2003,44:963-978.
  • 5Yao A, Kohmoto O, Oyama T, et al. Characteristic effects of alpha1-beta1,2-adrenergic blocking agent, carvedilol, on [Ca2+] I in ventricular myocytes compared with those of timolol and atenolol. Circ J,2003,67:83-90.
  • 6Liu X, Callaerts VZ, Evans KL,et al. Chronic infusion of beta-adrenoceptor antagonist and inverse agonists decrease elevated protein kinase a activity in transgenic mice with cardiac-specific overexpression of human beta2-adrenoceptor. J Cardiovasc Pharmacol, 2002,40:448-455.
  • 7Consensus recommendations for the management of chronic heart failure.On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure[].The American Journal of Cardiology.1999
  • 8张麟,刘慧荣,赵荣瑞,张健,惠汝太,刘力生.扩张型心肌病抗心肌β_1与M_2受体自身抗体的初步研究[J].中华心血管病杂志,1998,26(1):15-17. 被引量:46
  • 9张麟,胡大一,史旭波,李静,曾文军,徐立,崔亮.心脏β_1和M_2受体自身抗体与心力衰竭的研究[J].中华内科杂志,2001,40(7):445-447. 被引量:38
  • 10张麟,吴雅峰,缪国斌,张磊,刘瑞红,刘秀兰.心力衰竭患者与心脏β_2、α_1肾上腺素能受体和血管紧张素Ⅱ1型受体的自身抗体[J].中华心血管病杂志,2003,31(1):17-20. 被引量:26

共引文献2469

同被引文献32

  • 1陈瑾,胡大一,张麟,刘秀兰,吴雅峰,李静.卡维地洛对心脏β_1、β_2和α_1受体自身抗体及心功能的影响[J].中华心血管病杂志,2005,33(6):498-501. 被引量:69
  • 2胡大一.CIBISⅢ研究临床意义解读[J].临床荟萃,2006,21(1):4-5. 被引量:6
  • 3赵民生,曹秀虹.β受体阻断药的不良反应及防治对策[J].中国执业药师,2006(2):30-31. 被引量:1
  • 4Valle CA, Ignasi CA. Targeting neuronal dysfimction and receptor maging[J]. Biotechnology, 2007, 16: 5-8.
  • 5Remme WJ, Riegger G, Hildebrandt P, et al. The benefits of early combination treatment ofcarvedilol and ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN)[J]. Cardiovasc Drugs Ther, 2004, 18(1): 57-66.
  • 6NesslerJ, NesslerB, KitlinskiM, etal. Concentration ofBNP, endothelin 1, pro-inflammatory cytokines (TNF-alpha, IL-6) and exercise capacity in patients'with heart failure treated with carvedilol[J]. Cardiol Pol, 2008, 66(2): 144-51.
  • 7Motte S, McEntee K, Naeije R. Endothelin receptor antagonists[J]. Pharmacol Ther, 2006, 110(3): 386-414.
  • 8Kelland NF, Webb DJ. Clinical trials of endothelin antagonists in heart failure: a question of dose?[J]. Exp Biol Med (Maywood), 2006, 231(6): 696-9.
  • 9Valle CA,Ignasi CA.Targeting neuronal dysfunction and receptor maging[J].Biotechnology,2007,16(1):5-8.
  • 10Remme WJ,Riegger G,Hildebrandt P,et al.The benefits of early combination treatment of carvedilol and ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction.The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial(CARMEN)[J].Cardiovasc Drugs Ther,2004,18(1):57-66.

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部